loading.........
 
Jerome Jabbour and Prescription Omega-3 for Potential Cardio-Vascular Disease Remediation
Jerome Jabbour and Prescription Omega-3 for Potential Cardio-Vascular Disease Remediation
Bedminster, NJ, Sep 26, 2018 AEST (ABN Newswire) - Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma (NYSEAMERICAN:MTNB). Matinas BioPharma proprietary, disruptive technology utilizes a lipid nano-crystal (LNC) platform technology which can encapsulate small molecule drugs, ologonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. Mr. Jabbour discusses the significance of Amarin's (NASDAQ:AMRN) recent share upsurge Monday after the biopharmaceutical company's fish oil capsule showed dramatic benefits to heart patients in a clinical trial. Prescription Omega 3 has a path to a possible 30 million potential users in the US alone.

To view the Video Audio, please visit:
http://www.abnnewswire.net/press/en/94736/Matinas


About Matinas BioPharma Holdings Inc

Matinas BioPharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal ("LNC") platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.

In addition, the Company's proprietary, disruptive technology utilizes lipid nano-crystal cochleates to encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn and Facebook.

    



About The Ellis Martin Report

Ellis Martin ReportThe Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.

     


Contact

INVESTOR CONTACT
Jenene Thomas
Jenene Thomas Communications, LLC
T: (833) 475-8247
E: mtnb@jtcir.com

Ellis Martin
Editor
E:martinreports@gmail.com
T: +1-310-430-1388
www.ellismartinreport.com


Related Companies

The Ellis Martin Report
Matinas BioPharma Holdings Inc
Amarin Corporation plc

ABN Newswire This Page Viewed:  (Last 7 Days: 186) (Last 30 Days: 716) (Since Published: 14200) 
ANALYTICS: LOGIN HERE

Matinas BioPharma Holdings Inc NEWS: RECENT VISITS (3532)

Social Media